Evofem signs Phexxi license agreement for Middle East with UAE’s Pharma 1

Evofem (EVFM) and private Emirati health care company Pharma 1 have signed a License and Supply Agreement for the Middle East rights to Phexxi, Evofem’s FDA-approved hormone-free contraceptive. Pharma 1 will have the exclusive commercialization rights for Phexxi in the Middle East, including the United Arab Emirates – UAE -, Kuwait, Saudi Arabia, Qatar and certain other countries in the region. Pharma 1 will be responsible for obtaining and maintaining any regulatory approvals required to market and sell Phexxi, and will handle all aspects of distribution, sales and marketing, pharmacovigilance and all other commercial functions in these countries. Phexxi is the first and only locally-acting contraceptive gel approved by the FDA. In December 2023, Evofem entered into a Merger Agreement with Aditxt (ADTX) under which Aditxt intends to acquire Evofem. The companies are targeting a September 30, 2024, closing.